Skip to content
Search

Latest Stories

Indian origin Leena Nair to join BT Board

BRITISH Indian Leena Nair will join the BT board as a non-executive director.

The top Unilever executive will also serve as a member of the remuneration, nominations, digital impact and sustainability committees of the group.


Her appointment takes effect from the end of BT’s annual general meeting on July 10.

Nair brings broad functional HR expertise to the BT board. She has an outstanding record in driving large scale change and transformation.

She has been chief human resources (HR) officer at Unilever, since March 2016 where she has overall responsibility for the global people agenda for Unilever’s 160,000 employees.

Nair is also a member of Unilever’s leadership executive.

Indian origin Nair has been a non-executive director of the UK department for business, energy and industrial strategy since 2018 and is the chair of its nominations and governance committee.

BT’s chairman Jan du Plessis, said: “We are delighted to welcome Leena to BT. She brings a deep understanding of the strategic and practical challenges of driving large scale cultural transformation, making her an excellent addition to the Board.”

Prior to her current role, Nair held a number of senior HR roles at Unilever.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less